“The cannabinoid receptor 2 (CB2) system is described to modulate various pathological conditions, including inflammation and fibrosis.
A series of new heterocyclic small-molecule CB2 receptor agonists were identified from a high-throughput screen…
A significant depletion of the three measured kidney markers indicated a protective role of CB2 receptor activation toward inflammatory kidney damage. Compound 39 was also protective in a model of renal fibrosis.
Oral treatment with 39 at 3 mg kg-1 per day significantly decreased the amount of fibrosis by ∼40 % which was induced by unilateral ureter obstruction.”